# US 2003/0225074 A1 · Dihetero-substituted metalloprotease inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225074 A1
- Document ID: US20030225074A1
- Status: Published application
- Kind: A1
- Application number: 10/396,775
- Filed: 2003-03-25
- Published: 2003-12-04
- Earliest claimed: 1999-03-03
- Assignees: The Procter & Gamble Company
- Inventors: Menyan Cheng; Neil Gregory Almstead; Michael George Natchus; Stanislaw Pikul; Biswanath De
- Web page: https://patentgrep.com/patent/US20030225074A1

## CPC

- C07D 213/70: Sulfur atoms
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 317/48: the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C 323/58: with amino groups bound to the carbon skeleton
- C07D 213/65: attached in position 3 or 5
- C07D 233/84: Sulfur atoms
- C07D 235/28: Sulfur atoms
- C07D 239/95: with hetero atoms directly attached in positions 2 and 4
- C07D 249/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 257/04: Five-membered rings
- C07D 263/58: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 271/113: with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D 277/74: Sulfur atoms substituted by carbon atoms
- C07D 285/08: 1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C07D 307/38: with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D 311/16: substituted in position 7
- C07D 333/34: Sulfur atoms
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 473/36: Sulfur atom
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): 1 where J, M, Q, T, W, X, Z, R1, R2, R3, R4, R4′, R5, R6, R6′, R7, m, and n have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also disclosed are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

## Claims

### Claim 1

A compound having a structure according to Formula (I)
161
wherein
(A) X is selected from —OH and —NHOH; or when J is -D-(CR14R14′)tR15 where is D is —O—, as defined below, X can optionally be a covalent bond which joins with J to form a 5 to 9 membered ring;
(B) W is selected from —S—, —O—, —N(R32)—, —C(R32)═C(R32′)—, —N═C(R32)—, and —N═N—, where R32 and R32′ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
(C) R1 is selected from hydrogen, hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and halogen;
(D) R2 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl;
(E) T is —(CR8R8′)p-A-(CR8″R8′″)qR9 where
(1) p is from 0 to about 4;
(2) q is from 0 to about 4;
(3) each R8, R8′, R8″, and R8′″ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl;
(4) R9 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and halogen; and
(5) A is selected from a covalent bond; —O—; —SOr— where r is 0, 1 or 2; and —NR10— where R10 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R10 can join with R9 to form a ring with 5 to 8 members and 1 to 3 heteroatoms; provided that when p is 0, A is a covalent bond;
(F) R3 is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and;
(G) each R4 and R4′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; and n is from 0 to about 4;
(H) R5 is —(CR11R11′)sR12 where
(1) s is from 0 to about 4;
(2) each R11 and R11′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl; and
(3) R12 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halogen, and GR13 where G is —O— or —S— and R13 is selected from hydrogen, alkyl, and aryl;
(I) J is -D-(CR14R14′),R15 where
(1) t is from 0 to about 4;
(2) D is selected from —O—; —SOu— where u is from 0 to 2; and —NR16— where R16 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R16 can join with R15 to form a ring with 5 to 8 members and 1 to 3 heteroatoms;
(3) each R14 and R14′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl; and
(4) R15 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and; or R15 can join with R13 to form an optionally substituted ring with 5 to 9 ring members of which from 2 to 3 are heteroatoms;
(J) each R6 and R6′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; and m is from 0 to about;
(K) R7 is —(CR17R17′)vR18 where
(1) v is from O to about 4;
(2) R17 and R17′ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl; and
(3) R18 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and halogen;
(L) M is -E-(CR19R19′)wR20 where
(1) w is from 0 to about 4;
(2) E is selected from a —O—; —SOx— where x is from 0 to 2; and —NR21— where R21 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R21 can join with R20 to form a ring with 5 to 8 members and 1 to 3 heteroatoms;
(3) each R19 and R19′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl; and
(4) R20 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
(M) Q is -G′-(CR22R22′)yR23 where
(1) y is from 0 to about 4;
(2) G′ is selected from a covalent bond; —O—; —SOz— where z is from 0 to 2; and —NR24— where R24 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R24 can join with R22 to form an optionally substituted ring with 5 to 8 ring members of which from 1 to 3 are heteroatoms;
(3) each R22 and R22′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl;
(4) R23 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and, or R23 can join with R20 to form a ring from 5 to 8 members with 1 to 3 heteroatoms; and
(N) Z is selected from
(1) cycloalkyl and heterocycloalkyl;
(2) D′-(CR25R25′)aR26 where
(a) a is from 0 to about 4;
(b) when a is from 0 to about 4 then D′ is selected from —C≡C—, —CH═CH—, —O—, and —S—, and when a is from 1 to about 4, then D is selected from —C≡C—, —CH═CH—, —N═N—, —O—, —S— and —SO2—;
(c) each R25 and R25′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; and
(d) R26 is selected from hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, heterocycloalkyl and cycloalkyl; and, if D′ is —C≡C— or —CH═CH—, then R26 may also be selected from —CONR27R27′ where (i) R27 and R27′ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or (ii) R27 and R27′, together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms;
(3) —NR28R28′ where
(a) R28 and R28′ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heteroalkyl and —C(O)-Q′-(CR29R29′)bR30 where
(i) b is from 0 to about 4;
(ii) Q′ is selected from a covalent bond and —NR31—; and
(iii) each R29 and R29′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; R30 and R31 (i) each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or (ii) R30 and R31, together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; or R28 and R31, together with the nitrogen atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 2 to 3 are heteroatoms; or
(c) R28 and R28′, together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; and
(4)
162
where
(a) E′ and Y are independently selected from —CH— and —N—;
(b) L is selected from —S—, —O—, —N(R35)—, —C(R35)═C(R35′)—, —N═C(R35)—, and —N═N—, where R35 and R35′ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
(c) c is from 0 to about 4;
(d) each R33 and R33′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy;
(e) A′ is selected from covalent bond, —O—, —SOd—, —C(O)—, —C(O)NR36—, —NR36—, and —NR36C(O)—; where d is from 0 to 2 and R36 is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, haloalkyl; and
(f) T′ is —(CR37R37′)e—R38 where e is from 0 to about 4; each R37 and R37′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, alkoxy and aryloxy; and R38 is selected from hydrogen, alkyl, alkenyl, alkynyl, halogen, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or R36 and R38, together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 atoms of which 1 to 3 are heteroatoms; or R35 and R38, together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 atoms of which 1 to 3 are heteroatoms;
or an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein W is selected from —S— and —CH═CH—.

### Claim 3 (depends on 2)

The compound of claim 2 wherein Z is selected from -D′-(CR25R25′)aR26; —NR28R28′;
163

### Claim 4 (depends on 3)

The compound of claim 3 wherein Z is -D′-(CR25R25′)R26 where D′ is selected from —C≡C—, —C═C— and —N═N—; a is 0; and R26 is selected from aryl, heteroaryl, heterocycloalkyl and cycloalkyl.

### Claim 5 (depends on 3)

The compound of claim 3 wherein Z is —NR28R28′ wherein R28 is hydrogen and R28′ is —C(O)-Q′-(CR29R29′)bR30 where Q′ is a covalent bond and b is 0.

### Claim 6 (depends on 5)

The compound of claim 5 wherein R30 is selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.

### Claim 7 (depends on 3)

The compound of claim 3 wherein Z is
164
where wherein E′ and Y are both —CH—, c is 0, L is —C(R35′)═C(R35)— and R35 and T′ join to form an optionally substituted 5-membered ring containing from 0 to 2 ring heteroatoms.

### Claim 8 (depends on 3)

The compound of claim 3 wherein Z is
165
where wherein E′ and Y are both —CH—, c is 0, and L is —HC═CH—.

### Claim 9 (depends on 3)

The compound of claim 3 wherein A′ is selected from a covalent bond, —O— and —S—.

### Claim 10 (depends on 3)

The compound of claim 3 wherein T′ is —(CR37R37′)e—R38 where e is 0 and R38 is selected from alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl.

### Claim 11 (depends on 1)

The compound of claim 1 wherein m and n are both 0.

### Claim 12 (depends on 1)

The compound of claim 1 wherein J is -D-(CR14R14′)tR15 and where t is 0; D is selected from —O—, —S—, SO2, and —N(R16)— where R16 is selected from hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; and R15 is selected from hydrogen, alkyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; or R16 joins with R15 to form a ring with 5 to 6 members of which 1 or 2 are heteroatoms.

### Claim 13 (depends on 1)

The compound of claim 1 wherein M is -E-(CR19R19′)wR20 where w is 0 or 1; each R19 and R19′ is hydrogen; E is selected from —O—, —S—, —SO2— and —N(R21)— where R21 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; and R20 is selected from hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; or R21 joins with R20 to form a 5 or 6 membered ring having 1 or 2 ring heteroatoms.

### Claim 14 (depends on 1)

The compound of claim 1 wherein Q is -G′-(CR22R22′)yR23 where y is 0; G′ is selected from a covalent bond, —O— and —S—; and R23 is selected from hydrogen and lower alkyl; or R23 joins with R20 to form a ring having 5 or 6 members with 1 or 2 ring heteroatoms.

### Claim 15 (depends on 1)

The compound of claim 1 wherein T is —(CR8R8′)p-A-(CR8″R8′″)qR9 where p is 1; q is 0 or 1; each R1, R8, R8′, and R8” is hydrogen; R9 is selected from hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; and A is selected from a covalent bond, —O—, —S— and —N(R10)— where R10 is selected from hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl; or R10 joins with R9 to form an optionally substituted ring having 5 or 6 ring members of which 1 or 2 are heteroatoms.

### Claim 16

A compound having a structure according to Formula (II)
166
wherein
(A) W is selected from —S—, —O—, —N(R32)—, —C(R32)═C(R32′)—, —N═C(R32)—, and —N═N—, where R32 and R32′ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
(B) J is -D-(CR14R14′)tR15 where
(1) t is from 0 to about 4;
(2) D is selected from —O—; —SOu— where u is from 0 to 2; and —N(R16)— where R16 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R16 can join with R15 to form a ring with 5 to 8 members and 1 to 3 heteroatoms;
(3) each R14 and R14′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl; and
(4) R15 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and; or R15 can join with R13 to form a ring with 5 to 9 members and contain from 2 to 3 heteroatoms;
(C) M is -E-(CR19R19′)wR20 where
(1) w is from 0 to about 4;
(2) E is selected from a —O—; —SOx— where x is from 0 to 2; and —N(R21)— where R21 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R21 can join with R20 to form a ring with 5 to 8 members and 1 to 3 heteroatoms;
(3) each R19 and R19′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl;
(4) R20 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and
(D) Z is selected from
(1) cycloalkyl and heterocycloalkyl;
(2) -D′-(CR25R25′)aR26 where
(a) a is from 0 to about 4;
(b) when a is from 0 to about 4 then D′ is selected from —C≡C—, —CH═CH—, —O—, and —S—, and when a is from 1 to about 4, then D is selected from —C≡C—, —CH═CH—, —N═N—, —O—, —S— and —SO2—;
(c) each R25 and R25′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; and
(d) R26 is selected from hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, heterocycloalkyl and cycloalkyl; and, if D′ is —C≡C— or —CH═CH—, then R26 may also be selected from —C(═O)NR27R27′ where (i) R27 and R27′ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or (ii) R27 and R27′, together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms;
(3) —NR28R28′ where
(a) R28 and R28′ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heteroalkyl and —C(O)-Q′-(CR29R29′)bR30 where
(i) b is from 0 to about 4;
(ii) Q′ is selected from a covalent bond and —N(R31)—; and
(iii) each R29 and R29′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; R30 and R31 (i) each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or (ii) R30 and R31, together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; or R28 and R31, together with the nitrogen atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; or
(b) R28 and R28′, together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; and
(4)
167
where
(a) E′ and Y are independently selected from —CH— and —N—;
(b) L is selected from —S—, —O—, —N(R35)—, —C(R35)═C(R35′)—, —N═C(R35)—, and —N═N—, where R35 and R35′ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
(c) c is from 0 to about 4;
(d) each R33 and R33′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy;
(e) A′ is selected from covalent bond, —O—, —SOd—, —C(O)—, —C(═O)N(R36)—, —N(R36)—, and —N(R36)C(═O)—; where d is from 0 to 2 and R36 is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, haloalkyl; and
(f) T′ is —(CR37R37′)e—R38 where e is from 0 to about 4; each R37 and R37′ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, alkoxy and aryloxy; and R38 is selected from hydrogen, alkyl, alkenyl, alkynyl, halogen, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or R36 and R3”, together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 atoms of which 1 to 3 are heteroatoms; or R35 and R38, together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 atoms of which 1 to 3 are heteroatoms;
or an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

### Claim 17 (depends on 16)

The compound of claim 16 wherein:
(A) W is selected from —S— and —CH═CH—;
(B) J is -D-(CR14R14′)tR15 and where t is 0; D is selected from —O—, —S—, SO2, and —N(R16)— where R16 is selected from hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; and R15 is selected from hydrogen, alkyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; or R16 can join with R15 to form an optionally substituted ring with 5 to 6 members of 1 or 2 are heteroatoms;
(C) M is -E-(CR19R19′)wR20 where w is 0 or 1; each R19 and R19′ is hydrogen; E is selected from —O—, —S—, —SO2— and N(R21) where R21 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; and R20 is selected from hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; or R21 can join with R20 to form an optionally substituted 5 or 6 membered ring having 1 or 2 ring heteroatoms.

### Claim 18 (depends on 17)

The compound of claim 17 wherein Z is
168
where wherein E′ and Y are both —CH—, c is 0, L is —C(R35′)═C(R35)— and R35 and T′ join to form an optionally substituted 5-membered ring containing from 0 to 2 ring heteroatoms.

### Claim 19 (depends on 17)

The compound of claim 17 wherein Z is
169
and wherein E′ and Y are both —CH—, c is 0, and L is —HC═CH—.

### Claim 20 (depends on 17)

The compound of claim 17 wherein A′ is selected from a covalent bond, —O— and —S—.

### Claim 21 (depends on 17)

The compound of claim 17 wherein T′ is —(CR37R37′)e—R38 where e is 0 and R38 is selected from alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl.

### Claim 22

A compound selected from the group consisting of:
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(4′-(Methylthio)[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(4′-Phenoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(4′-(2-Methoxyethoxy)[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(4′-(2-(1-Pyrrolidinyl)ethoxy)[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(1,1′:4′,1″-Terphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(3′,4′-(Methylenedioxy)[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(3′-Ethoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[[4-[(4-Methoxyphenyl)ethynyl]phenyl]sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[[4-[(4-Methylphenyl)ethynyl]phenyl]sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[[4-(Phenylazo)phenyl]sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(4′-Chloro[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thiazolylthio]-pentanoic acid;
2-[(4′-Bromo[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thiazolylthio]-pentanoic acid;
2-[(4′-Trifluoromethyl[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thiazolylthio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(phenylthio)-pentanoic acid;
2-[[(1,1′-biphenyl)-4-yl]sulfonyl]amino-4-hydroxy-5-(phenylthio)-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(benzylthio)-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(benzyl)sulfonyl]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(phenylamino)-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(1H-1,2,4-triazol-3-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(phenylamino)-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonylamino-4-hydroxy-5-[(2-imidazolyl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[2-(5-methylbenzimidazolyl)]thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(4(3H)-quinazolinonyl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(6-ethoxy-2-benzothiazolyl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-benzothiazolylthio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-benzoxazolylthio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-benzimidazolylthio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-(1-methyl-1H-imidazol-2-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(1-methyl-1H-tetrazol-5-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(4-methyl-4(H)-1,2,4-triazol-3-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-(methylthio)-1,3,4-thiadiazol-2-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thienylthio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-phenyl-1,3,4-oxadiazol-2-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[([-(4-methoxylphenyl)-1H-tetrazol-1-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(6-chloro-2-benzoxazolyl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[3-(methylthio)-1,2,4-thiadiazol-5-yl]thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[5-(4-pyridinyl)-1,3,4-oxadiazol-2-yl]thio)-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-methoxybenzothiazoly-2-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-methoxybenzimidazol-2-yl)thio]-pentanoic acid;
2-[(4′-Methoxy 1,1′-biphenyl-3-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-phenyl-1H-1,2,4-triazol-3-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-methyl-3-furanyl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(4-methoxyphenyl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyrimidin-2-ylthio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-ylsulfonyl]amino-4-hydroxy-5-[4,6-dimethylpyrimidin-2-ylthio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyridin-2-ylthiopentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[purin-2-ylthiopentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl-4-yl)sulfonyl]amino-4-hydroxy-5-[4-methylcoumarin-7-ylthio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[(4-methoxyphenyl)methyl]thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[(4-fluorophenyl)methyl]thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[furfurylthio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thienyl)methylthio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-phenoxypentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyridin-3-yloxy]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyrimidin-2-yloxy]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-4-methyl-5-[(1-N-methyl-imidazol-2-yl-thio)-methyl]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(4′-Thiomethoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(2-120 thiazolyl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(4-methyl-4(H)-1,2,4-triazol-3-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(4-methyl-4(H)-1,2,4-triazol-3-yl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-4-methyl-5-[(3-trifluoromethylpyridin-2-yl)-thiomethyl]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(3-trifluoromethyl)-2-pyridyl-thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]-N-methyl-amino-4-hydroxy-5-130 (phenylthio)-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(4′-Thiomethoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;
2-[(4′-Methoxy[1,1′-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(4-methyl-4(H)-1,2,4-triazol-3-yl)thio]-pentanoic acid;
2-[(4′-Methoxy-[1,1′-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-phenoxymethyl-[1,3]dioxan-2-yl)-propionic acid;
2-[(4′-Bromo-[1,1′-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-phenoxymethyl-[1,3]dioxan-2-yl)-propionic acid;
2-[(4′-Methoxy-[1,1′-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-thiophenoxymethyl-[1,3]dioxan-2-yl)-propionic acid;
2-[(4′-Methoxy-[1,1′-biphenyl]-4-yl)-sulfonyl]-amino-3-[2-(2-oxo-azepan-1-ylmethyl)-[1,3]dioxan-2-yl]-propionic acid, and
2-[(4′-Methoxy-[1,1′-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-phenoxymethyl-[1,3]dioxan-2-yl)-propionic acid.

### Claim 23 (depends on 1)

A pharmaceutical composition comprising:
(a) a safe and effective amount of a compound of claim 1; and
(b) a pharmaceutically-acceptable carrier.

### Claim 24 (depends on 2)

A pharmaceutical composition comprising:
(a) a safe and effective amount of a compound of claim 2; and
(b) a pharmaceutically-acceptable carrier.

### Claim 25 (depends on 11)

A pharmaceutical composition comprising:
(a) a safe and effective amount of a compound of claim 11; and
(b) a pharmaceutically-acceptable carrier.

### Claim 26 (depends on 16)

A pharmaceutical composition comprising:
(a) a safe and effective amount of a compound of claim 16; and
(b) a pharmaceutically-acceptable carrier.

### Claim 27 (depends on 22)

A pharmaceutical composition comprising:
(a) a safe and effective amount of a compound of claim 22; and
(b) a pharmaceutically-acceptable carrier.

### Claim 28 (depends on 1)

A method for preventing or treating a disease associated with unwanted metalloprotease activity in a mammalian subject, the method comprising administering to said subject a safe and effective amount of a compound of claim 1.

### Claim 29 (depends on 2)

A method for preventing or treating a disease associated with unwanted metalloprotease activity in a mammalian subject, the method comprising administering to said subject a safe and effective amount of a compound of claim 2.

### Claim 30 (depends on 16)

A method for preventing or treating a disease associated with unwanted metalloprotease activity in a human or other animal subject, the method comprising administering to said subject a safe and effective amount of a compound of claim 16.

### Claim 31 (depends on 22)

A method for treating a disease associated with unwanted metalloprotease activity in a mammalian subject, the method comprising administering to said subject a safe and effective amount of a compound of claim 22.

### Claim 32 (depends on 1)

A method for treating a disorder modulated by metalloproteases, wherein the disorder is chosen from the group consisting of arthritis, cancer, cardiovascular disorders, skin disorders, ocular disorders, inflammation and gum disease, by administering to a mammal in need of such treatment a safe and effective amount of a metalloprotease inhibitor according to claim 1.

### Claim 33 (depends on 32)

The method for treating a disorder according to claim 32, wherein the disorder is arthritis, and is chosen from the group consisting of osteoarthritis and rheumatoid arthritis.

### Claim 34 (depends on 32)

The method for treating a disorder according to claim 32, wherein the disorder is cancer, and the treatment prevents or arrests tumor growth and metastasis.

### Claim 35 (depends on 32)

The method for treating a disorder according to claim 32, wherein the disorder is a cardiovascular disorder chosen from the group consisting of dilated cardiomyopathy, congestive heart failure, atherosclerosis, plaque rupture, reperfusion injury, ischemia, chronic obstructive pulmonary disease, angioplasty restenosis, and aortic aneurysm.

### Claim 36 (depends on 32)

The method for treating a disorder according to claim 32, wherein the disorder is an ocular disorder, and is chosen from the group consisting of corneal ulceration, lack of corneal healing, macular degeneration, retinopathy, and pterygium.

### Claim 37 (depends on 32)

The method for treating a disorder according to claim 32, wherein the disorder is gum disease, and is chosen from the group consisting of periodontal disease and gingivitis.

### Claim 38 (depends on 32)

The method for treating a disorder, according to claim 32, wherein the disorder is skin a disorder chosen from the group consisting of wrinkle repair and prevention, U.V. skin damage, epidermolysis bullosa, psoriasis, sclerodema, atopic dermatitis, and scarring.

### Claim 39 (depends on 1)

A method for preventing the loosening of prosthetic devices chosen from the group comprising joint replacements and dental prosthesis by administering to a mammal in need of such treatment, a safe and effective amount of a metalloprotease inhibitor according to claim 1.

### Claim 40 (depends on 32)

The method for treating inflammatory conditions according to claim 32, wherein said inflammatory condition is chosen from the group consisting of inflammatory bowel disease, Crohn's Disease, ulcerative colitis, pancreatitis, diverticulitis, acne inflammation, bronchitis, arthritis, and asthma.

### Claim 41 (depends on 1)

A method of treating multiple sclerosis, comprising administering to a mammal in need of such treatment, a safe and effective amount of a metalloprotease inhibitor according to claim 1.

### Claim 42 (depends on 1)

A method for treating musculoskeletal disease or cachexia comprising administering to a mammal in need of such treatment, a safe and effective amount of a metalloprotease inhibitor according to claim 1.
